Actively Recruiting
Response-Adapted Neoadjuvant Treatment Using Culmerciclib and Aromatase Inhibitors for Highly Proliferative ER-PositiveHER2-Negative Early Breast Cancer
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-06-01
45
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a response-adapted treatment strategy using culmerciclib combined with aromatase inhibitors for patients with highly proliferative estrogen receptor-positive and HER2-negative early breast cancer. This phase II study aims to tailor treatments based on how well the tumor responds to initial therapy, with the goal of improving outcomes and minimizing unnecessary exposure to ineffective drugs. The approach addresses the varied sensitivity to endocrine therapy seen in this breast cancer subtype. All participants first receive neoadjuvant treatment with culmerciclib plus endocrine therapy. After an initial treatment phase, tumor response is assessed through biological and clinical evaluations. Patients who show a good response continue the same treatment, while those with a poor response switch to alternative therapies before surgery. This adaptive design helps to optimize treatment plans for each patient. Participants will undergo assessments including tumor biopsies, clinical evaluations, and safety monitoring throughout the study. Researchers will measure outcomes such as complete cell cycle arrest after 4 weeks, pathological response at 24 weeks, and long-term event-free survival over approximately five years. Safety and tolerability will be monitored for about three years. The study involves regular follow-up visits to track treatment effectiveness and side effects over time.
CONDITIONS
Brief Title
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
Research Team
Y
Yunxiang Zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here